Abstract:CD147 also known as EMMPRIN, basigin, and HAb18G, is a single-chain type I transmembrane protein shown to be overexpressed in aggressive human cancers of CNS, head and neck, breasts, lungs, gastrointestinal, genitourinary, skin, hematological, and musculoskeletal. In these malignancies, the molecule is integral to the diverse but complimentary hallmarks of cancer: it is pivotal in cancerous proliferative signaling, growth propagation, cellular survival, replicative immortality, angiogenesis, metabolic reprogramming, immune evasion, invasion, and metastasis. CD147 also has regulatory functions in cancer-enabling characteristics such as DNA damage response (DDR) and immune evasion. These neoplastic functions of CD147 are executed through numerous and sometimes overlapping molecular pathways: it transduces signals from upstream molecules or ligands such as cyclophilin A (CyPA), CD98, and S100A9; activates a repertoire of downstream molecules and pathways including matrix metalloproteinases (MMPs)-2,3,9, hypoxia-inducible factors (HIF)-1/2α, PI3K/Akt/mTOR/HIF-1α, and ATM/ATR/p53; and also functions as an indispensable chaperone or regulator to monocarboxylate, fatty acid, and amino acid transporters. Interestingly, induced loss of functions to CD147 prevents and reverses the acquired hallmarks of cancer in neoplastic diseases. Silencing of Cd147 also alleviates known resistance to chemoradiotherapy exhibited by malignant tumors like carcinomas of the breast, lung, pancreas, liver, gastric, colon, ovary, cervix, prostate, urinary bladder, glioblastoma, and melanoma. Targeting CD147 antigen in chimeric and induced-chimeric antigen T cell or antibody therapies is also shown to be safer and more effective. Moreover, incorporating anti-CD147 monoclonal antibodies in chemoradiotherapy, oncolytic viral therapy, and oncolytic virus-based-gene therapies increases effectiveness and reduces on and off-target toxicity. This study advocates the expedition and expansion by further exploiting the evidence acquired from the experimental studies that modulate CD147 functions in hallmarks of cancer and cancer-enabling features and strive to translate them into clinical practice to alleviate the emergency and propagation of cancer, as well as the associated clinical and social consequences.

Involvement of CD147 in Regulation of Multidrug Resistance to P‐gp Substrate Drugs and in Vitro Invasion in Breast Cancer Cells

Up‐regulation of CD147 and Matrix Metalloproteinase‐2, ‐9 Induced by P‐glycoprotein Substrates in Multidrug Resistant Breast Cancer Cells

Interaction Between Cd147 And P-Glycoprotein And Their Regulation By Ubiquitination In Breast Cancer Cells

[CD147 and Matrix Metallo-Proteinase (MMP) 2 and MMP9 Expression in Multidrug Resistant Breast Cancer Cells Treated with P-glycoprotein Substrate Drugs].

CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells.

Extracellular matrix metalloproteinase inducer (CD147/BSG/EMMPRIN)-induced radioresistance in cervical cancer by regulating the percentage of the cells in the G2/m phase of the cell cycle and the repair of DNA Double-strand Breaks (DSBs).

Involvement Of Egfr In The Promotion Of Malignant Properties In Multidrug Resistant Breast Cancer Cells

RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro

ResearchRNAi-mediated silencing of CD 147 inhibits tumor cell proliferation , invasion and increases chemosensitivity to cisplatin in SGC 7901 cells in vitro

Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells.

EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.

Relationship Between the Expression of P-gp and that of CD147, MMPs in None Small Cell Lung Cancer

CD147: an integral and potential molecule to abrogate hallmarks of cancer

Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway.

ERK1/2 Signalling Pathway is Involved in CD147-mediated Gastric Cancer Cell Line SGC7901 Proliferation and Invasion

Expression and CD147,MMP-9 and P-Erk in Invasive Ductal Carcinoma of Breast and Its Significance

Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer

The Invasion And Metastasis Promotion Role Of Cd97 Small Isoform In Gastric Carcinoma

Downregulation of CD 147 Expression by RNA Interference Inhibits HT 29 Cell Proliferation , Invasion and Tumorigenicity in Vitro and in Vivo

Inhibition of CD147 expression by RNA interference reduces proliferation, invasion and increases chemosensitivity in cancer stem cell-like HT-29 cells

Downregulation of caveolin-1 promotes murine breast cancer cell line progression by highly glycosylated CD147